VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2022 | Safety and efficacy of a CLDN18.2-specific CAR T-cell therapy in GI adenocarcinoma

Gregory P. Botta, MD, PhD, UC San Diego Medical Center, San Diego, CA, presents findings from a Phase I trial (NCT04404595) of a claudin 18.2 (CLDN18.2)-specific chimeric antigen receptor (CAR) T-cell therapy in patients with advanced gastric and pancreatic adenocarcinoma. The recruited patients typically have three or more lines of previous therapy and no treatment-related deaths were reported, with no gastritis or pancreatitis reported. A patient with gastric cancer had a complete response and disease control was observed in over half of patients with both forms of adenocarcinoma. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter